Free stock market and financial news API
Instant access to global stock market and finance news also including funds, crypto and more along with comprehensive sentiment analysis.
{
"meta": {
"found": 3587,
"returned": 5,
"limit": 5,
"page": 1
},
"data": [
{
"uuid": "dc802494-d1c2-406f-958f-ae6f54c86ba9",
"title": "HP vs. Dell: Which AI Infrastructure Stock Is the Better Buy?",
"description": "The two stocks cater to different types of investors, but there's a clear winner for people who want the potential for higher returns.",
"keywords": "Dell, AI infrastructure, AI capabilities, Dell Technologies",
"snippet": "HP (NYSE: HPQ) and Dell (NYSE: DELL) are both competing in the AI PC market. Both of them have dominated the PC industry for years, but those same computers wil...",
"url": "https://finance.yahoo.com/technology/ai/articles/hp-vs-dell-ai-infrastructure-155000340.html",
"image_url": "https://s.yimg.com/lo/mysterio/api/28C42346C816F280225AFA49EBF02E21CE8B4F2190A4210984D73E73D39917B3/subgraphmysterio/resizefill_w1200_h675;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fmotleyfool.com%2Fcf442b89cf44fd36086c91849189f3bb",
"language": "en",
"published_at": "2026-07-04T15:50:00.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "HPQ",
"name": "HP Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 21.863417,
"sentiment_score": 0.8922,
"highlights": [
{
"highlight": "HP (<em>NYSE</em>: <em>HPQ</em>) and Del[+325 characters]",
"sentiment": 0.8922,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "98a14671-f9c8-40a2-b8df-0225b7e9b905",
"title": "Argus Maintains Buy Rating on Alphabet (GOOGL) Stock",
"description": "Alphabet Inc. (NASDAQ:GOOGL) is one of the Best AI and Technology Stocks to Buy Now. On June 23, Argus maintained a “Buy” rating and a price objective of $440 on the company’s stock.",
"keywords": "",
"snippet": "When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.\n\nFast forward...",
"url": "https://www.insidermonkey.com/blog/argus-maintains-buy-rating-on-alphabet-googl-stock-1795307/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/09/19163428/GOOGL-insidermonkey-1695155666632.jpg",
"language": "en",
"published_at": "2026-07-04T14:08:56.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "GOOGL",
"name": "Alphabet Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 66.63632,
"sentiment_score": 0.36345,
"highlights": [
{
"highlight": "Even as we admire what Tesla, Nvidia, <e[+254 characters]",
"sentiment": 0.7269,
"highlighted_in": "main_text"
},
{
"highlight": "Argus Maintains Buy Rating on <em>Alphabet</em> (<em>GOOGL</em>) Stock",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "a7ce5858-e5fa-4665-9213-ac57d940acf1",
"title": "Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?",
"description": "Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 2026.",
"keywords": "Iovance Biotherapeutics, Free cash flow, Heartflow, shareholders’ equity",
"snippet": "Healthcare is changing through AI and personalized cell therapy. Which of these high-growth innovators represents the better risk-adjusted opportunity for your ...",
"url": "https://finance.yahoo.com/healthcare/articles/heartflow-vs-iovance-biotherapeutics-healthcare-140459182.html",
"image_url": "https://s.yimg.com/lo/mysterio/api/12E0AFF1FD3FCC3015D588E9D8536DF46C224A939FBC1839E1AEFCEE626CC28C/subgraphmysterio/resizefill_w1200_h800;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fmotleyfool.com%2Fc8a12b310311b5cefb46ed67e02c2172",
"language": "en",
"published_at": "2026-07-04T14:04:59.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVS",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 36.705315,
"sentiment_score": 0.3612,
"highlights": [
{
"highlight": "To support its pipeline, Iovance maintai[+208 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "IOVA",
"name": "Iovance Biotherapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 79.90675,
"sentiment_score": 0.285367,
"highlights": [
{
"highlight": "(NASDAQ:HTFL) and <em>Iovance</em> <em>B[+331 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "The case for <em>Iovance</em> <em>Biothe[+289 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Iovance</em> <em>Biotherapeutics</em>: Which Healthcare Stock Is a Better Buy in 2026?",
"sentiment": 0.4404,
"highlighted_in": "title"
}
]
},
{
"symbol": "NVSEF",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 24.172476,
"sentiment_score": 0.3612,
"highlights": [
{
"highlight": "To support its pipeline, Iovance maintai[+199 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NVSN.MX",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 24.172504,
"sentiment_score": 0.3612,
"highlights": [
{
"highlight": "To support its pipeline, Iovance maintai[+199 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0K9E.L",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 24.17243,
"sentiment_score": 0.3612,
"highlights": [
{
"highlight": "To support its pipeline, Iovance maintai[+199 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NOVN.SW",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "ch",
"type": "equity",
"industry": "Healthcare",
"match_score": 24.172455,
"sentiment_score": 0.3612,
"highlights": [
{
"highlight": "To support its pipeline, Iovance maintai[+199 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "N1VS34.SA",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 24.17238,
"sentiment_score": 0.3612,
"highlights": [
{
"highlight": "To support its pipeline, Iovance maintai[+199 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NVSD.BA",
"name": "NOVARTIS AG",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 24.172377,
"sentiment_score": 0.3612,
"highlights": [
{
"highlight": "To support its pipeline, Iovance maintai[+199 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "ff2afa11-d84a-4772-93af-487fbf6f0ce0",
"title": "Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?",
"description": "Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships.",
"keywords": "Pharmaceuticals, Free cash flow, Therapeutics, Recursion, Duchenne muscular dystrophy",
"snippet": "In FY 2025, revenue reached approximately $74.7 million, representing nearly 27% growth over the previous fiscal year. Despite this growth, the company reported...",
"url": "https://finance.yahoo.com/healthcare/articles/dyne-therapeutics-vs-recursion-pharmaceuticals-134109812.html",
"image_url": "https://s.yimg.com/lo/mysterio/api/B1A86361BA78AC8BC8AF6A5052479920E6BB47FB7841223D05A9F4B1E44B653A/subgraphmysterio/resizefill_w1200_h800;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fmotleyfool.com%2F1c1aefc0787053027d428c725e185484",
"language": "en",
"published_at": "2026-07-04T13:41:09.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVDA",
"name": "NVIDIA Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 13.457401,
"sentiment_score": -0.101733,
"highlights": [
{
"highlight": "It also maintains technical relationship[+211 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "* Or when <em>Nvidia</em> made this list[+243 characters]",
"sentiment": 0.2942,
"highlighted_in": "main_text"
},
{
"highlight": "The Motley Fool has positions in and rec[+231 characters]",
"sentiment": -0.5994,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "DYN",
"name": "Dyne Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 62.786575,
"sentiment_score": 0.29595,
"highlights": [
{
"highlight": "<em>Dyne</em> <em>Therapeutics</em> oper[+259 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Dyne</em> <em>Therapeutics</em> focu[+313 characters]",
"sentiment": 0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "Choosing between <em>Dyne</em> <em>Thera[+230 characters]",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "Risk profile comparison\n\n<em>Dyne</em> <[+282 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Dyne</em> <em>Therapeutics</em>, mea[+292 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Dyne</em> <em>Therapeutics</em> may [+96 characters]",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "But given Dyne appears closer to getting[+119 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Before you buy stock in <em>Dyne</em> <e[+307 characters]",
"sentiment": 0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Dyne</em> <em>Therapeutics</em> vs. [+132 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Dyne</em> <em>Therapeutics</em> vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?",
"sentiment": 0.4404,
"highlighted_in": "title"
}
]
},
{
"symbol": "SNY",
"name": "Sanofi",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.704947,
"sentiment_score": 0,
"highlights": [
{
"highlight": "It also maintains technical relationship[+202 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RXRX",
"name": "Recursion Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 61.713596,
"sentiment_score": 0.3859,
"highlights": [
{
"highlight": "<em>Recursion</em> <em>Pharmaceuticals</[+273 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Dyne Therapeutics focuses on solving del[+313 characters]",
"sentiment": 0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "Choosing between Dyne Therapeutics (NASD[+230 characters]",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Recursion</em> <em>Pharmaceuticals</[+212 characters]",
"sentiment": 0.8221,
"highlighted_in": "main_text"
},
{
"highlight": "Valuation comparison\n\n<em>Recursion</em>[+221 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Metric Dyne Therapeutics <em>Recursion</[+278 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Recursion</em> <em>Pharmaceuticals</[+110 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Recursion</em> <em>Pharmaceuticals</em>: Which Development Stage Pharma Stock Is a Better Buy in 2026?",
"sentiment": 0.4404,
"highlighted_in": "title"
}
]
},
{
"symbol": "MRK",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 15.552312,
"sentiment_score": -0.2997,
"highlights": [
{
"highlight": "It also maintains technical relationship[+211 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The Motley Fool has positions in and rec[+231 characters]",
"sentiment": -0.5994,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "HTGC",
"name": "Hercules Capital, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 17.085255,
"sentiment_score": 0.6908,
"highlights": [
{
"highlight": "The company relies on a loan agreement w[+180 characters]",
"sentiment": 0.6908,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "789e1b9b-1cf6-4ce4-acd9-215c4aff2ee8",
"title": "McKesson: The Healthcare Supplier On My Buy List This Summer, As Growth Accelerates (NYSE:MCK)",
"description": "McKesson (MCK) is rated a buy, offering capital growth and dividend potential, underpinned by robust top-line and EPS growth.",
"keywords": "",
"snippet": "Albert Anthony is the pen name of a business author on Amazon and his newest book is \"How To Pick Stocks: 8 Steps For Long-Term Investing with Fundamental & Tec...",
"url": "https://seekingalpha.com/article/4919852-mckesson-the-healthcare-supplier-on-my-buy-list-this-summer-as-growth-accelerates",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222153/image_2194222153.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2026-07-04T15:39:12.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "MCK",
"name": "McKesson Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 68.9781,
"sentiment_score": 0.3818,
"highlights": [
{
"highlight": "<em>McKesson</em>: The Healthcare Supplier On My Buy List This Summer, As Growth Accelerates (<em>NYSE:MCK</em>)",
"sentiment": 0.3818,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "d8575c79-56e1-4201-a95d-91c106bca94c",
"title": "Why Ultra-High-Yield UPS Is Investing $48 Million to Control the Temperature",
"description": "United Parcel Service is in the middle of a turnaround, and changing its customer base has been a key part of the process.",
"keywords": "United Parcel Service, quarterly earnings results, profit margins, turnaround effort",
"snippet": "United Parcel Service (NYSE: UPS) is deeply unloved on Wall Street, with the stock down 50% from its 2022 high. To be fair, the parcel delivery company has been...",
"url": "https://finance.yahoo.com/markets/stocks/articles/why-ultra-high-yield-ups-153500638.html",
"image_url": "https://s.yimg.com/lo/mysterio/api/7E58B4204F1EE0E40BA6B15BF63474213797CCCF507D25007957066AB640D130/subgraphmysterio/resizefill_w1200_h818;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fmotleyfool.com%2Fdebced60b74236efd702d38586e9c341",
"language": "en",
"published_at": "2026-07-04T15:35:00.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "UPS",
"name": "United Parcel Service, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 30.414093,
"sentiment_score": 0.3892,
"highlights": [
{
"highlight": "<em>United</em> <em>Parcel</em> <em>Serv[+346 characters]",
"sentiment": 0.3892,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "7b49c43a-5eac-419f-887e-13c98f313c67",
"title": "'Criticism is welcome, rumours are not': Puri on E20 fuel buzz, engine damage claims",
"description": "India Business News: Union petroleum and natural gas minister Hardeep Singh Puri on Saturday pushed back against social media claims surrounding ethanol-blended fuel, sayi.",
"keywords": "E20 fuel, ethanol-blended fuel, Hardeep Singh Puri, biofuel programme, vehicle engine damage",
"snippet": "Union petroleum and natural gas minister Hardeep Singh Puri on Saturday pushed back against social media claims surrounding ethanol-blended fuel, saying that th...",
"url": "https://timesofindia.indiatimes.com/business/india-business/criticism-is-welcome-rumours-are-not-puri-on-e20-fuel-buzz-engine-damage-claims/articleshow/132183548.cms",
"image_url": "https://static.toiimg.com/thumb/msid-132183543,width-1280,height-720,resizemode-6,overlay-toi_sw,pt-32,y_pad-600/photo.jpg",
"language": "en",
"published_at": "2026-07-04T15:29:39.000000Z",
"source": "timesofindia.indiatimes.com",
"relevance_score": null,
"entities": [
{
"symbol": "F",
"name": "Ford Motor Company",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 23.280102,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Henry Ford, the owner of the <em>Ford</e[+327 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "a443dd8b-b352-4fc8-af17-20c6988e8f4b",
"title": "9 Most Oversold Strong Buy-Rated Stocks to Invest In Now",
"description": "Oversold stocks are getting more attention as investors look for names where selling pressure may have gone further than the fundamentals justify.",
"keywords": "",
"snippet": "In this article, we will look at the 9 Most Oversold Strong Buy-Rated Stocks to Invest In Now.\n\nOversold stocks are getting more attention as investors look for...",
"url": "https://www.insidermonkey.com/blog/9-most-oversold-strong-buy-rated-stocks-to-invest-in-now-1793570/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/09/30195653/NDAQ-insidermonkey-1696118210528.jpg",
"language": "en",
"published_at": "2026-07-04T15:15:47.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "JD",
"name": "JD.com, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 47.072838,
"sentiment_score": -0.091067,
"highlights": [
{
"highlight": "On June 23, 2026, <em>JD.com</em>, <em>I[+328 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Late in May, Brussels was set to launch [+212 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>JD.com</em>, <em>Inc</em>. (<em>NASD[+124 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ICE",
"name": "Intercontinental Exchange, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 57.10376,
"sentiment_score": 0.32395,
"highlights": [
{
"highlight": "<em>Intercontinental</em> <em>Exchange</[+219 characters]",
"sentiment": -0.128,
"highlighted_in": "main_text"
},
{
"highlight": "On June 29, <em>Intercontinental</em> <e[+173 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "On June 22, TD Cowen lowered its price t[+327 characters]",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Intercontinental</em> <em>Exchange</[+269 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "JDCMF",
"name": "JD.com, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 30.782103,
"sentiment_score": -0.091067,
"highlights": [
{
"highlight": "On June 23, 2026, <em>JD.com</em>, <em>I[+319 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Late in May, Brussels was set to launch [+203 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>JD.com</em>, <em>Inc</em>. (NASDAQ:J[+115 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "14b78bc5-37e1-4df9-afbf-978d052e59f9",
"title": "3 Resilient Defense Stocks to Buy in July",
"description": "Defense stocks are the rare corner of the market where geopolitical anxiety, fiscal generosity and multi-year revenue visibility all converge at once. With the Fiscal Year 2027 investment request by the Department of War totaling $756.8 billion, and President Trump declaring that “our Military Budget for the year 2027 should not be $1 Trillion Dollars, ... 3 Resilient Defense Stocks to Buy in July",
"keywords": "Lockheed Martin, NYSE, RTX, Defense stocks, top 10 AI stocks, Department of War",
"snippet": "Quick Read\n\nRTX logged its eighth straight quarterly beat with a 17% Q1 EPS surprise, while ten NOC directors bought stock amid a 12% year-to-date pullback.\n\nLM...",
"url": "https://finance.yahoo.com/markets/stocks/articles/3-resilient-defense-stocks-buy-130055491.html",
"image_url": "https://s.yimg.com/lo/mysterio/api/3CB68FA738ABF3953CF25017AADA24DCFA758BA4C1FCAC54C010D1CBF3DE0192/subgraphmysterio/resizefill_w1200_h670;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2F24_7_wall_st__718%2F21ddeb1d867721294f0e8dd7e427380d",
"language": "en",
"published_at": "2026-07-04T13:00:55.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "LMT",
"name": "Lockheed Martin Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 47.799282,
"sentiment_score": 0.4109,
"highlights": [
{
"highlight": "<em>Lockheed</em> <em>Martin</em> (<em>N[+355 characters]",
"sentiment": 0.4109,
"highlighted_in": "main_text"
}
]
}
]
}
]
}
]
}
Example response
marketaux is Incredibly Powerful and Easy-to-Use
Get the latest financial and stock market news from top news sources. Use our API to access clean and relevant financial news and analysis.
Over 200,000 entities tracked every minute
We track over 80 global markets with news from more than 5,000 quality sources in 30+ languages.
Concise analysis of only relevant text allows us to generate superior analytics for stocks and other entities.
VIEW SUPPORTED ENTITIESAdvanced language processing technology
Our NLP technology allows us to identify critical details within news articles.
Our tracked entities include stocks, indices, ETFs, commodities, mutual funds, futures, currencies and crypto, complete with relevant analysis.
GET FREE API KEY
Frequent Asked Questions
Our service is 100% free to use on our free plan - no payment details are required.
Each time the API is used to access financial news or analysis data, 1 API request is added to your daily usage. The number of requests allowed for your account depends on which subscription plan you are on.
Yes, paying annually will provide you 2 months free per year (20% discount). To register for a yearly plan, simply go to our pricing page while logged in and select a plan and you will be prompted to pay monthly or annually.